Artiva develops natural killer cell therapies for autoimmune diseases and cancers, based in San Diego, California. ARTV reports earnings on Wed, Nov 11, 2026. In the past 30 days there were 1 dark pool print.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 29 | Jefferies | Downgrade | Hold | |
| Oct 27 | Wedbush | Downgrade | Hold | |
| Jun 8 | Needham | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in ARTV in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARTV is in one of them and how their past ARTV trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARTV in an article yet. Here's the latest on the wider market.
About Artiva Biotherapeutics
Artiva is a biotechnology company based in San Diego, California, that is developing cell therapies made from natural killer cells, a type of immune cell. Its lead product candidate, AlloNK, is made from donor cells, frozen and shipped ready for use, and is designed to work alongside antibody medicines to deplete B cells. The company is testing AlloNK in clinical trials for autoimmune diseases such as rheumatoid arthritis and Sjögren's disease, and it also has programs aimed at cancers. The intended patients are people with these conditions, and the product is not yet approved for sale.
- Headquarters
- San Diego, CA